Publication:
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Simple item page
dc.contributor.authorKissling, Esther
dc.contributor.authorHooiveld, Mariëtte
dc.contributor.authorSandonis-Martin, Virginia
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorWilliam, Naoma
dc.contributor.authorVilcu, Ana-Maria
dc.contributor.authorMazagatos, Clara
dc.contributor.authorDomegan, Lisa
dc.contributor.authorde Lusignan, Simon
dc.contributor.authorMeijer, Adam
dc.contributor.authorMachado, Ausenda
dc.contributor.authorBrytting, Mia
dc.contributor.authorCasado, Itziar
dc.contributor.authorMurray, Josephine-L K
dc.contributor.authorBelhillil, Sylvie
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorO'Donnell, Joan
dc.contributor.authorTsang, Ruby
dc.contributor.authorde Lange, Marit
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorRiess, Maximilian
dc.contributor.authorCastilla Catalán, Jesús
dc.contributor.authorHamilton, Mark
dc.contributor.authorFalchi, Alessandra
dc.contributor.authorPozo Sanchez, Francisco
dc.contributor.authorDunford, Linda
dc.contributor.authorCogdale, Jade
dc.contributor.authorJansen, Tessa
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorEnkirch, Theresa
dc.contributor.authorBurgui, Cristina
dc.contributor.authorSigerson, Debbie
dc.contributor.authorBlanchon, Thierry
dc.contributor.authorMartínez Ochoa, Eva María
dc.contributor.authorConnell, Jeff
dc.contributor.authorEllis, Joanna
dc.contributor.authorvan Gageldonk-Lafeber, Rianne
dc.contributor.authorKislaya, Irina
dc.contributor.authorRose, Angela Mc
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-MOVE-COVID-19 primary care study team
dc.contributor.funderUnión Europea. Comisión Europea. H2020
dc.date.accessioned2022-04-25T11:41:02Z
dc.date.available2022-04-25T11:41:02Z
dc.date.issued2021
dc.description.abstractWe measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThis project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673.es_ES
dc.format.number29es_ES
dc.format.page2100670es_ES
dc.format.volume26es_ES
dc.identifier.citationEuro Surveill. 2021;26(29):2100670.es_ES
dc.identifier.doi10.2807/1560-7917.ES.2021.26.29.2100670es_ES
dc.identifier.e-issn1560-7917es_ES
dc.identifier.journalEuro Surveillance: bulletin Europeen sur les maladies transmissibleses_ES
dc.identifier.pubmedID34296676es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14166
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/101003673/EUes_ES
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19es_ES
dc.subjectEuropees_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectMulticentre studyes_ES
dc.subjectTest-negative designes_ES
dc.subjectVaccine effectivenesses_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshSARS-CoV-2es_ES
dc.subject.meshAdultes_ES
dc.subject.meshAgedes_ES
dc.subject.meshCOVID-19 Vaccineses_ES
dc.subject.meshEuropees_ES
dc.subject.meshHumanses_ES
dc.subject.meshPrimary Health Carees_ES
dc.titleVaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021es_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationca996557-6935-4e00-8837-5e399b58653a
relation.isAuthorOfPublicatione177bf8c-3734-480b-a2ae-4ae67491776c
relation.isAuthorOfPublicatione77e1f2d-b4e2-4ba5-a853-c2795850dcae
relation.isAuthorOfPublication5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isAuthorOfPublication.latestForDiscoveryca996557-6935-4e00-8837-5e399b58653a
relation.isFunderOfPublicationa418cf3b-f427-4376-a75f-01dba9bb944f
relation.isFunderOfPublication.latestForDiscoverya418cf3b-f427-4376-a75f-01dba9bb944f
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
VaccineEffectivenessAgainstSymptomatic_2021.pdf
Size:
143.85 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Centro Nacional de Microbiología (CNM)
Centro Nacional de Epidemiología (CNE)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)